{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:10:18Z","timestamp":1792822218413,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.blre.2022.101036","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:41:14Z","timestamp":1669902074000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?"],"prefix":"10.1016","volume":"59","author":[{"given":"Prajwal","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2022.101036_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2022.101036_bb0010","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.101036_bb0015","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Ibrahim","year":"2018","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.101036_bb0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.blre.2022.101036_bb0025","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.101036_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2022.101036_bb0035","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1182\/blood-2021-148054","article-title":"Preliminary results by age group of treatment with CPX-351 plus Venetoclax in adults with newly diagnosed AML: subgroup analysis of the V-FAST phase 1b master trial","volume":"138","author":"Pullarkat","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0040","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2021-151648","article-title":"Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients with FLT3 mutated acute myeloid leukemia (AML)","volume":"138","author":"Abuasab","year":"2021","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.101036_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2022.101036_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"The Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2022.101036_bb0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0060","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A phase 1b study","author":"Garcia","year":"2020"},{"issue":"15","key":"10.1016\/j.blre.2022.101036_bb0065","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.blre.2022.101036_bb0070","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of Venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2022.101036_bb0075","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2022.101036_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"34","key":"10.1016\/j.blre.2022.101036_bb0085","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene."},{"issue":"1","key":"10.1016\/j.blre.2022.101036_bb0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"issue":"10","key":"10.1016\/j.blre.2022.101036_bb0095","first-page":"1007","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood, The J Am Soc Hematol"},{"issue":"8","key":"10.1016\/j.blre.2022.101036_bb0100","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.blre.2022.101036_bb0110","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.blre.2022.101036_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou Eleni","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0120","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0125","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.101036_bb0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2021-145639","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with Venetoclax combined with hypomethylating agents","volume":"138","author":"Pollyea","year":"2021","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2022.101036_bb0135","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.blre.2022.101036_bb0140","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0145","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2022.101036_bb0155","first-page":"1","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.blre.2022.101036_bb0160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to Venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0165","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI114865","article-title":"Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy","volume":"86","author":"Carrera","year":"1990","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0170","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with Venetoclax rescues Venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2022.101036_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136872","article-title":"Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia","volume":"136","author":"Moujalled","year":"2020","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2022.101036_bb0180","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica."},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0185","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0190","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: are we there yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr Med Chem"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.101036_bb0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2019-123711","article-title":"Updated results from the Venetoclax (Ven) in combination with Idasanutlin (Idasa) arm of A Phase 1b trial in elderly patients (Pts) with relapsed or refractory (R\/R) AML ineligible for cytotoxic chemotherapy","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101036_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100689","article-title":"Strategies to reduce the on-target platelet toxicity of Bcl-xL inhibitors: PROTACs, SNIPERs and prodrug-based approaches","author":"Negi","year":"2022","journal-title":"ChemBioChem"},{"issue":"11","key":"10.1016\/j.blre.2022.101036_bb0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2022.101036_bb0210","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.26314","article-title":"Development of TP53 mutations over the course of therapy for acute myeloid leukemia","volume":"96","author":"Alwash","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2022.101036_bb0215","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.blre.2022.101036_bb0220","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0225","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2021-153286","article-title":"Long term follow-up and combined phase 2 results of Eprenetapopt (APR-246) and Azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood."},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.101036_bb0230","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.101036_bb0235","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(21)01694-3","article-title":"AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results","volume":"21","author":"Sallman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.blre.2022.101036_bb0240","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2021-147479","article-title":"Combined blockade of CD47-Sirpa interaction by 5F9 (magrolimab) and azacitidine\/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models","volume":"138","author":"Jia","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II study of Azacitidine (AZA) with Venetoclax (VEN) and magrolimab (magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0250","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1096\/fasebj.2021.35.S1.02109","article-title":"Preclinical characterization of TP-0903, a novel multikinase inhibitor, in TP53 mutant acute myeloid leukemia","volume":"35","author":"Eisenmann","year":"2021","journal-title":"FASEB J"},{"issue":"23","key":"10.1016\/j.blre.2022.101036_bb0255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140169","article-title":"TP-0903 is active in models of drug-resistant acute myeloid leukemia","volume":"5","author":"Jeon","year":"2020","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.blre.2022.101036_bb0260","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after Venetoclax and Azacitidine for patients with treatment-Na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2022.101036_bb0265","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Abhishek","year":"2020","journal-title":"Haematologica."},{"issue":"22","key":"10.1016\/j.blre.2022.101036_bb0270","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2022.101036_bb0275","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Raghuveer Singh","year":"2020","journal-title":"Haematologica."},{"issue":"25","key":"10.1016\/j.blre.2022.101036_bb0280","first-page":"6089","article-title":"Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process","volume":"119","author":"Rahmani","year":"2012","journal-title":"Blood, The J Am Soc Hematol"},{"issue":"8","key":"10.1016\/j.blre.2022.101036_bb0285","first-page":"826","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Can"},{"key":"10.1016\/j.blre.2022.101036_bb0290","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk acute myeloid leukemia by suppressing MCL-1","author":"Janssen","year":"2022","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.101036_bb0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2022.101036_bb0300","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2021-153571","article-title":"A triplet combination of Azacitidine, Venetoclax and Gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a phase I\/II study","volume":"138","author":"Short","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.101036_bb0305","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/S2152-2650(21)01684-0","article-title":"AML-162: efficacy and safety of Venetoclax in combination with Gilteritinib for relapsed\/refractory FLT3-mutated acute myeloid leukemia: updated analyses of a phase 1b study","volume":"21","author":"Altman","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leukemia"},{"key":"10.1016\/j.blre.2022.101036_bb0310","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2021-153426","article-title":"Quizartinib (quiz) with Decitabine (DAC) and Venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) - RAS\/MAPK mutations continue to drive primary and secondary resistance","volume":"138","author":"Yilmaz","year":"2021","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2022.101036_bb0315","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V128.22.1069.1069","article-title":"Final results of the chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"128","author":"Perl","year":"2016","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0320","first-page":"1176","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Can"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2022.101036_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to Venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"516","key":"10.1016\/j.blre.2022.101036_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.blre.2022.101036_bb0340","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood.2020007651","article-title":"Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia","volume":"137","author":"Niu","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.101036_bb0345","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.17185","article-title":"How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)","volume":"193","author":"Dillon","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2022.101036_bb0350","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:57Z","timestamp":1759436937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":70,"alternative-id":["S0268960X22001102"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.101036","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}